Cite
Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd
MLA
Aditya Raju, et al. “Real-World Outcomes and Factors Impacting Treatment Choice in Relapsed and/or Refractory Multiple Myeloma (RRMM): A Comparison of VRd, KRd, and IRd.” Expert Review of Hematology, vol. 13, no. 4, Jan. 2020, pp. 421–33. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....1474a0ec9f6076c282bc6f64b7d364e6&authtype=sso&custid=ns315887.
APA
Aditya Raju, Evangelos Terpos, Marlo Blazer, Meletios A. Dimopoulos, Hui Huang, Pieter Sonneveld, Ajai Chari, Antonio Palumbo, Dorothy Romanus, Paul G. Richardson, Roman Hájek, Lauren E. Cain, Sikander Ailawadhi, & Eileen Farrelly. (2020). Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. Expert Review of Hematology, 13(4), 421–433.
Chicago
Aditya Raju, Evangelos Terpos, Marlo Blazer, Meletios A. Dimopoulos, Hui Huang, Pieter Sonneveld, Ajai Chari, et al. 2020. “Real-World Outcomes and Factors Impacting Treatment Choice in Relapsed and/or Refractory Multiple Myeloma (RRMM): A Comparison of VRd, KRd, and IRd.” Expert Review of Hematology 13 (4): 421–33. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....1474a0ec9f6076c282bc6f64b7d364e6&authtype=sso&custid=ns315887.